Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood-based tests, data sets and analytics. The company is engaged in the clinical liquid biopsy market with its Guardant360 and GuardantOMNI tests. The company's Guardant360 test is a molecular diagnostic test measuring a number of cancer-related genes and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. In addition, the company is developing tests from its LUNAR-1 program for minimal residual disease and recurrence detection in cancer survivors, and its LUNAR-2 program for early detection of cancer.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.